Overcoming drug resistance and treating advanced prostate cancer

Julius Semenas, Cinzia Allegrucci, Stephen A. Boorjian, Nigel P. Mongan, Jenny Liao Persson

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Most of the prostate cancers (PCa) in advanced stage will progress to castration-resistant prostate cancer (CRPC). Within CRPC group, 50-70% of the patients will develop bone metastasis in axial and other regions of the skeleton. Once PCa cells spread to the bone, currently, no treatment regimens are available to eradicate the metastasis, and cancer- related death becomes inevitable. In 2012, it is estimated that there will be 28,170 PCa deaths in the United States. Thus, PCa bone metastasis-associated clinical complications and treatment resistance pose major clinical challenges. In this review, we will present recent findings on the molecular and cellular pathways that are responsible for bone metastasis of PCa. We will address several novel mechanisms with a focus on the role of bone and bone marrow microenvironment in promoting PCa metastasis, and will further discuss why prostate cancer cells preferentially metastasize to the bone. Additionally, we will discuss novel roles of several key pathways, including angiogenesis and extracellular matrix remodeling in bone marrow and stem cell niches with their relationship to PCa bone metastasis and poor treatment response. We will evaluate how various chemotherapeutic drugs and radiation therapies may allow aggressive PCa cells to gain advantageous mutations leading to increased survival and rendering the cancer cells to become resistant to treatment. The novel concept relating several key survival and invasion signaling pathways to stem cell niches and treatment resistance will be reviewed. Lastly, we will provide an update of several recently developed novel drug candidates that target metastatic cancer microenvironments or niches, and discuss the advantages and significance provided by such therapeutic approaches in pursuit of overcoming drug resistance and treating advanced PCa.

Original languageEnglish (US)
Pages (from-to)1308-1323
Number of pages16
JournalCurrent Drug Targets
Volume13
Issue number10
DOIs
StatePublished - 2012

Fingerprint

Drug Resistance
Prostatic Neoplasms
Bone
Pharmaceutical Preparations
Neoplasm Metastasis
Bone and Bones
Stem Cell Niche
Stem cells
Bone Neoplasms
Castration
Cells
Drug therapy
Therapeutics
Radiotherapy
Tumor Microenvironment
Survival
Skeleton
Bone Marrow Cells
Extracellular Matrix
Neoplasms

Keywords

  • Bone nietasrasis
  • Novel therapy
  • Prostate cancer
  • Treatment resistance

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Semenas, J., Allegrucci, C., Boorjian, S. A., Mongan, N. P., & Persson, J. L. (2012). Overcoming drug resistance and treating advanced prostate cancer. Current Drug Targets, 13(10), 1308-1323. https://doi.org/10.2174/138945012802429615

Overcoming drug resistance and treating advanced prostate cancer. / Semenas, Julius; Allegrucci, Cinzia; Boorjian, Stephen A.; Mongan, Nigel P.; Persson, Jenny Liao.

In: Current Drug Targets, Vol. 13, No. 10, 2012, p. 1308-1323.

Research output: Contribution to journalArticle

Semenas, J, Allegrucci, C, Boorjian, SA, Mongan, NP & Persson, JL 2012, 'Overcoming drug resistance and treating advanced prostate cancer', Current Drug Targets, vol. 13, no. 10, pp. 1308-1323. https://doi.org/10.2174/138945012802429615
Semenas J, Allegrucci C, Boorjian SA, Mongan NP, Persson JL. Overcoming drug resistance and treating advanced prostate cancer. Current Drug Targets. 2012;13(10):1308-1323. https://doi.org/10.2174/138945012802429615
Semenas, Julius ; Allegrucci, Cinzia ; Boorjian, Stephen A. ; Mongan, Nigel P. ; Persson, Jenny Liao. / Overcoming drug resistance and treating advanced prostate cancer. In: Current Drug Targets. 2012 ; Vol. 13, No. 10. pp. 1308-1323.
@article{7b51b935bfa7460c83476d6409cf4481,
title = "Overcoming drug resistance and treating advanced prostate cancer",
abstract = "Most of the prostate cancers (PCa) in advanced stage will progress to castration-resistant prostate cancer (CRPC). Within CRPC group, 50-70{\%} of the patients will develop bone metastasis in axial and other regions of the skeleton. Once PCa cells spread to the bone, currently, no treatment regimens are available to eradicate the metastasis, and cancer- related death becomes inevitable. In 2012, it is estimated that there will be 28,170 PCa deaths in the United States. Thus, PCa bone metastasis-associated clinical complications and treatment resistance pose major clinical challenges. In this review, we will present recent findings on the molecular and cellular pathways that are responsible for bone metastasis of PCa. We will address several novel mechanisms with a focus on the role of bone and bone marrow microenvironment in promoting PCa metastasis, and will further discuss why prostate cancer cells preferentially metastasize to the bone. Additionally, we will discuss novel roles of several key pathways, including angiogenesis and extracellular matrix remodeling in bone marrow and stem cell niches with their relationship to PCa bone metastasis and poor treatment response. We will evaluate how various chemotherapeutic drugs and radiation therapies may allow aggressive PCa cells to gain advantageous mutations leading to increased survival and rendering the cancer cells to become resistant to treatment. The novel concept relating several key survival and invasion signaling pathways to stem cell niches and treatment resistance will be reviewed. Lastly, we will provide an update of several recently developed novel drug candidates that target metastatic cancer microenvironments or niches, and discuss the advantages and significance provided by such therapeutic approaches in pursuit of overcoming drug resistance and treating advanced PCa.",
keywords = "Bone nietasrasis, Novel therapy, Prostate cancer, Treatment resistance",
author = "Julius Semenas and Cinzia Allegrucci and Boorjian, {Stephen A.} and Mongan, {Nigel P.} and Persson, {Jenny Liao}",
year = "2012",
doi = "10.2174/138945012802429615",
language = "English (US)",
volume = "13",
pages = "1308--1323",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "10",

}

TY - JOUR

T1 - Overcoming drug resistance and treating advanced prostate cancer

AU - Semenas, Julius

AU - Allegrucci, Cinzia

AU - Boorjian, Stephen A.

AU - Mongan, Nigel P.

AU - Persson, Jenny Liao

PY - 2012

Y1 - 2012

N2 - Most of the prostate cancers (PCa) in advanced stage will progress to castration-resistant prostate cancer (CRPC). Within CRPC group, 50-70% of the patients will develop bone metastasis in axial and other regions of the skeleton. Once PCa cells spread to the bone, currently, no treatment regimens are available to eradicate the metastasis, and cancer- related death becomes inevitable. In 2012, it is estimated that there will be 28,170 PCa deaths in the United States. Thus, PCa bone metastasis-associated clinical complications and treatment resistance pose major clinical challenges. In this review, we will present recent findings on the molecular and cellular pathways that are responsible for bone metastasis of PCa. We will address several novel mechanisms with a focus on the role of bone and bone marrow microenvironment in promoting PCa metastasis, and will further discuss why prostate cancer cells preferentially metastasize to the bone. Additionally, we will discuss novel roles of several key pathways, including angiogenesis and extracellular matrix remodeling in bone marrow and stem cell niches with their relationship to PCa bone metastasis and poor treatment response. We will evaluate how various chemotherapeutic drugs and radiation therapies may allow aggressive PCa cells to gain advantageous mutations leading to increased survival and rendering the cancer cells to become resistant to treatment. The novel concept relating several key survival and invasion signaling pathways to stem cell niches and treatment resistance will be reviewed. Lastly, we will provide an update of several recently developed novel drug candidates that target metastatic cancer microenvironments or niches, and discuss the advantages and significance provided by such therapeutic approaches in pursuit of overcoming drug resistance and treating advanced PCa.

AB - Most of the prostate cancers (PCa) in advanced stage will progress to castration-resistant prostate cancer (CRPC). Within CRPC group, 50-70% of the patients will develop bone metastasis in axial and other regions of the skeleton. Once PCa cells spread to the bone, currently, no treatment regimens are available to eradicate the metastasis, and cancer- related death becomes inevitable. In 2012, it is estimated that there will be 28,170 PCa deaths in the United States. Thus, PCa bone metastasis-associated clinical complications and treatment resistance pose major clinical challenges. In this review, we will present recent findings on the molecular and cellular pathways that are responsible for bone metastasis of PCa. We will address several novel mechanisms with a focus on the role of bone and bone marrow microenvironment in promoting PCa metastasis, and will further discuss why prostate cancer cells preferentially metastasize to the bone. Additionally, we will discuss novel roles of several key pathways, including angiogenesis and extracellular matrix remodeling in bone marrow and stem cell niches with their relationship to PCa bone metastasis and poor treatment response. We will evaluate how various chemotherapeutic drugs and radiation therapies may allow aggressive PCa cells to gain advantageous mutations leading to increased survival and rendering the cancer cells to become resistant to treatment. The novel concept relating several key survival and invasion signaling pathways to stem cell niches and treatment resistance will be reviewed. Lastly, we will provide an update of several recently developed novel drug candidates that target metastatic cancer microenvironments or niches, and discuss the advantages and significance provided by such therapeutic approaches in pursuit of overcoming drug resistance and treating advanced PCa.

KW - Bone nietasrasis

KW - Novel therapy

KW - Prostate cancer

KW - Treatment resistance

UR - http://www.scopus.com/inward/record.url?scp=84866530142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866530142&partnerID=8YFLogxK

U2 - 10.2174/138945012802429615

DO - 10.2174/138945012802429615

M3 - Article

C2 - 22746994

AN - SCOPUS:84866530142

VL - 13

SP - 1308

EP - 1323

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 10

ER -